Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Fitzpatrick, A. & Tutt, A. (2019). Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Therapeutic advances in medical oncology, Vol.11, pp. 175883591988258-175883591988258.  show abstract

Evans, R., Flores-Borja, F., Nassiri, S., Miranda, E., Lawler, K., Grigoriadis, A., Monypenny, J., Gillet, C., Owen, J., Gordon, P., et al. (2019). Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer. Cell reports, Vol.27 (7), pp. 1967-1978.e4.

Wu, Y., Kyle-Cezar, F., Woolf, R.T., Naceur-Lombardelli, C., Owen, J., Biswas, D., Lorenc, A., Vantourout, P., Gazinska, P., Grigoriadis, A., et al. (2019). An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Science translational medicine, Vol.11 (513), pp. eaax9364-eaax9364.  show abstract

Ilieva, K.M., Fazekas‐Singer, J., Bax, H.J., Crescioli, S., Montero‐Morales, L., Mele, S., Sow, H.S., Stavraka, C., Josephs, D.H., Spicer, J.F., et al. (2019). AllergoOncology: Expression platform development and functional profiling of an anti‐HER2 IgE antibody. Allergy, Vol.74 (10), pp. 1985-1989.

Chabanon, R.M., Muirhead, G., Krastev, D.B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019). PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer. Journal of clinical investigation, Vol.129 (3), pp. 1211-1228.

Tutt, A. (2018). Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. Ann oncol, Vol.29 (1), pp. 18-21.

Muliaditan, T., Opzoomer, J.W., Caron, J., Okesola, M., Kosti, P., Lall, S., Van Hemelrijck, M., Dazzi, F., Tutt, A., Grigoriadis, A., et al. (2018). Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical cancer research, Vol.24 (7), pp. 1617-1628.

Natrajan, R., Tutt, A.N. & Lord, C.J. (2018). Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. Cancer discov, Vol.8 (3), pp. 272-275.  show abstract

Rodrigues, N.V., Correia, D.V., Mensurado, S., Nóbrega-Pereira, S., deBarros, A., Kyle-Cezar, F., Tutt, A., Hayday, A.C., Norell, H., Silva-Santos, B., et al. (2018). Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells. Cancer immunology research, Vol.6 (4), pp. 448-457.

Irshad, S., Flores-Borja, F., Lawler, K., Monypenny, J., Evans, R., Male, V., Gordon, P., Cheung, A., Gazinska, P., Noor, F., et al. (2017). RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. Cancer research, Vol.77 (5), pp. 1083-1096.

Gracio, F., Burford, B., Gazinska, P., Mera, A., Mohd Noor, A., Marra, P., Gillett, C., Grigoriadis, A., Pinder, S., Tutt, A., et al. (2017). Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients’ survival. Scientific reports, Vol.7 (1).

Ju, Y.S., Martincorena, I., Gerstung, M., Petljak, M., Alexandrov, L.B., Rahbari, R., Wedge, D.C., Davies, H.R., Ramakrishna, M., Fullam, A., et al. (2017). Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, Vol.543 (7647), pp. 714-718.

Davies, H., Glodzik, D., Morganella, S., Yates, L.R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A.M., et al. (2017). HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature medicine, Vol.23 (4), pp. 517-525.

Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. (2017). Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. The lancet, Vol.389 (10087), pp. 2430-2442.

Coles, C.E., Griffin, C.L., Kirby, A.M., Titley, J., Agrawal, R.K., Alhasso, A., Bhattacharya, I.S., Brunt, A.M., Ciurlionis, L., Chan, C., et al. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The lancet, Vol.390 (10099), pp. 1048-1060.

Yates, L.R., Knappskog, S., Wedge, D., Farmery, J.H., Gonzalez, S., Martincorena, I., Alexandrov, L.B., Van Loo, P., Haugland, H.K., Lilleng, P.K., et al. (2017). Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer cell, Vol.32 (2), pp. 169-+.

Eisenblaetter, M., Flores-Borja, F., Lee, J.J., Wefers, C., Smith, H., Hueting, R., Cooper, M.S., Blower, P.J., Patel, D., Rodriguez-Justo, M., et al. (2017). Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment. Theranostics, Vol.7 (9), pp. 2392-2401.

Fittall, M.W., Levi, D., Clifford, A., Shah, V., Cheung, A., Tutt, A. & Karagiannis, S.N. (2016). Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers. Immune regulation of t cell responses/ evolving concepts in cancer immunology, .

Fittall, M.W., Cheung, A., Petranyi, G.M., Rodriguez-Dominguez, D., Bax, H.J., Karagiannis, P., Ilieva, K.M., Tutt, A. & Karagiannis, S.N. (2016). Abstract A090: Exploring folate receptor α immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies. Tumor antigens for targeting: insight from genomics, .

Marra, P., Mathew, S., Catchpole, S., Facchetti, A. & Tutt, A. (2016). Abstract A093: Interferon gamma and post-translational modifications control the dynamics and plasma membrane association of IL15RA expressed by Triple Negative Breast Cancer (TNBC). Immune regulation of t cell responses/ evolving concepts in cancer immunology, .

Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L.B., Martin, S., Wedge, D.C., et al. (2016). Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, Vol.534 (7605), pp. 47-54.

Watkins, J., Tutt, A. & Grigoriadis, A. (2016). Tandem duplications contribute to not one but two distinct phenotypes. Proc natl acad sci u s a, Vol.113 (36), pp. E5257-E5258.

Flores-Borja, F., Irshad, S., Gordon, P., Wong, F., Sheriff, I., Tutt, A. & Ng, T. (2016). Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. Journal of immunology research, Vol.2016, pp. 1-14.  show abstract

Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., Gillett, C., Pinder, S., Vanoli, F., Jasin, M., et al. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer discovery, Vol.5 (5), pp. 488-505.

Tutt, A. (2015). PG 5 02 Targeting DNA repair pathways. The breast, Vol.24, pp. S9-S10.

Ju, Y.S., Tubio, J.M., Mifsud, W., Fu, B., Davies, H.R., Ramakrishna, M., Li, Y., Yates, L., Gundem, G., Tarpey, P.S., et al. (2015). Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome research, Vol.25 (6), pp. 814-824.

Di Leo, A., Curigliano, G., Diéras, V., Malorni, L., Sotiriou, C., Swanton, C., Thompson, A., Tutt, A. & Piccart, M. (2015). New approaches for improving outcomes in breast cancer in Europe. The breast, Vol.24 (4), pp. 321-330.

Schouten, P.C., Grigoriadis, A., Kuilman, T., Mirza, H., Watkins, J.A., Cooke, S.A., van Dyk, E., Severson, T.M., Rueda, O.M., Hoogstraat, M., et al. (2015). Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular oncology, Vol.9 (7), pp. 1274-1286.

Tutt, A. (2015). IN16 RESURRECTING PARP INHIBITION. The breast, Vol.24, pp. S27-S27.

Soady, K.J., Kendrick, H., Gao, Q., Tutt, A., Zvelebil, M., Ordonez, L.D., Quist, J., Tan, D.W., Isacke, C.M., Grigoriadis, A., et al. (2015). Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast cancer research, Vol.17 (1).

Lord, C.J., Tutt, A.N. & Ashworth, A. (2015). Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annual review of medicine, Vol.66 (1), pp. 455-470.

Marra, P., Mathew, S., Grigoriadis, A., Wu, Y., Kyle-Cezar, F., Watkins, J., Rashid, M., De Rinaldis, E., Hessey, S., Gazinska, P., et al. (2014). IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers. Cancer research, Vol.74 (17), pp. 4908-4921.

Irshad, S., Gillett, C., Pinder, S.E., A'hern, R.P., Dowsett, M., Ellis, I.O., Bartlett, J.M., Bliss, J.M., Hanby, A., Johnston, S., et al. (2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast cancer res treat, Vol.144 (2), pp. 331-341.  show abstract

Parikh, J., Selmi, M., Charles-Edwards, G., Glendenning, J., Ganeshan, B., Verma, H., Mansi, J., Harries, M., Tutt, A. & Goh, V., et al. (2014). Changes in Primary Breast Cancer Heterogeneity May Augment Midtreatment MR Imaging Assessment of Response to Neoadjuvant Chemotherapy. Radiology, Vol.272 (1), pp. 100-112.

Vantourout, P., Willcox, C., Turner, A., Swanson, C.M., Haque, Y., Sobolev, O., Grigoriadis, A., Tutt, A. & Hayday, A. (2014). Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway. Science translational medicine, Vol.6 (231).

Kyle, F., Hessey, S., Wu, Y., Tutt, A. & Hayday, A. (2014). Characterising the immune landscape of healthy breast tissue and breast tumours in humans. Immunology, Vol.143, pp. 144-144.

Kiuchi, T., Ortiz-Zapater, E., Monypenny, J., Matthews, D.R., Nguyen, L.K., Barbeau, J., Coban, O., Lawler, K., Burford, B., Rolfe, D.J., et al. (2014). The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science signaling, Vol.7 (339).

Marlow, R., Honeth, G., Lombardi, S., Cariati, M., Hessey, S., Pipili, A., Mariotti, V., Buchupalli, B., Foster, K., Bonnet, D., et al. (2013). A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells. Cancer research, Vol.73 (23), pp. 6886-6899.

Jack, R.H., Davies, E.A., Renshaw, C., Tutt, A., Grocock, M.J., Coupland, V.H. & Moller, H. (2013). Differences in breast cancer hormone receptor status in ethnic groups: A London population. European journal of cancer, Vol.49 (3), pp. 696-702.

Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-., et al. (2013). Signatures of mutational processes in human cancer. Nature, Vol.500 (7463), pp. 415-421.

Eccles, S.A., Aboagye, E.O., Ali, S., Anderson, A.S., Armes, J., Berditchevski, F., Blaydes, J.P., Brennan, K., Brown, N.J., Bryant, H.E., et al. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast cancer research, Vol.15 (5).

Yau, C., Sninsky, J., Kwok, S., Wang, A., Degnim, A., Ingle, J.N., Gillett, C., Tutt, A., Waldman, F., Moore, D., et al. (2013). An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast cancer research, Vol.15 (5).

Kaufmann, M., von Minckwitz, G., Mamounas, E.P., Cameron, D., Carey, L.A., Cristofanilli, M., Denkert, C., Eiermann, W., Gnant, M., Harris, J.R., et al. (2012). Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of surgical oncology, Vol.19 (5), pp. 1508-1516.

Vichapat, V., Garmo, H., Holmberg, L., Fentiman, I.S., Tutt, A., Gillett, C. & Luechtenborg, M. (2012). Patterns of metastasis in women with metachronous contralateral breast cancer. British journal of cancer, Vol.107 (2), pp. 221-223.

Tutt, A. (2012). The biology of BRCA-associated breast cancer. Breast, Vol.21, pp. S2-S2.

Turner, N.C. & Tutt, A.N. (2012). Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?. Breast cancer research, Vol.14 (6).

Robertson, L., Hanson, H., Seal, S., Warren-Perry, M., Hughes, D., Howell, I., Turnbull, C., Houlston, R., Shanley, S., Butler, S., et al. (2012). BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br j cancer, Vol.106 (6), pp. 1234-1238.  show abstract

Grigoriadis, A., Mackay, A., Noel, E., Wu, P.J., Natrajan, R., Frankum, J., Reis-Filho, J.S. & Tutt, A. (2012). Molecular characterisation of cell line models for triple-negative breast cancers. Bmc genomics, Vol.13.

Marlow, R., Cariati, M., Honeth, G.M., Buchupalli, B., Lombardi, S., Foster, K., Bonnet, D., Purushotham, A., Tutt, A. & Dontu, G., et al. (2012). Abstract LB-307: Modeling the breast cancer metastatic niche. Tumor biology, .

Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K.S., Viale, G., Loi, S., Bradbury, I., Bliss, J.M., Azim, H.A., Ellis, P., et al. (2012). Dissecting the heterogeneity of triple-negative breast cancer. J clin oncol, Vol.30 (15), pp. 1879-1887.  show abstract

Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., et al. (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, Vol.486 (7403), pp. 400-+.

Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012). The Life History of 21 Breast Cancers. Cell, Vol.149 (5).

Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L.A., et al. (2012). Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, Vol.149 (5), pp. 979-993.

Irshad, S., Grigoriadis, A., Lawler, K., Ng, T. & Tutt, A. (2012). Profiling the Immune Stromal Interface in Breast Cancer and Its Potential for Clinical Impact. Breast care, Vol.7 (4), pp. 273-280.

Tutt, A. (2011). PARP inhibitors - walking them through to adjuvant. Breast, Vol.20, pp. S1-S1.

Balmana, J., Domchek, S.M., Tutt, A. & Garber, J.E. (2011). Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers. Cancer discovery, Vol.1 (1), pp. 29-34.

Irshad, S., Ashworth, A. & Tutt, A. (2011). Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert review of anticancer therapy, Vol.11 (8), pp. 1243-1251.

Vichapat, V., Gillett, C., Fentiman, I.S., Tutt, A., Holmberg, L. & Luechtenborg, M. (2011). Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. European journal of cancer, Vol.47 (13), pp. 1919-1927.

Domchek, S.M., Mitchell, G., Lindeman, G.J., Tung, N.M., Balmana, J., Isakoff, S.J., Schmutzler, R., Audeh, M.W., Loman, N., Scott, C., et al. (2011). Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of clinical oncology, Vol.29 (32), pp. 4224-4226.

Glendenning, J. & Tutt, A. (2011). PARP inhibitors - current status and the walk towards early breast cancer. Breast, Vol.20, pp. S12-S19.

Tutt, A. (2011). ROLE OF PARP INHIBITORS IN TN ADVANCED BREAST CANCER. Breast, Vol.20, pp. S17-S17.

Irshad, S., Ellis, P. & Tutt, A. (2011). Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current opinion in oncology, Vol.23 (6), pp. 566-577.

Vichapat, V., Garmo, H., Holmberg, L., Fentiman, I.S., Tutt, A., Gillett, C. & Luechtenborg, M. (2011). Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast cancer research and treatment, Vol.130 (2), pp. 609-618.

Julien, S., Ivetic, A., Grigoriadis, A., Qize, D., Burford, B., Sproviero, D., Picco, G., Gillett, C., Papp, S.L., Schaffer, L., et al. (2011). Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers. Cancer research, Vol.71 (24), pp. 7683-7693.

Tutt, A. (2011). Abstract PL04-02: Synthetic lethality: Targeting DNA repair mechanisms in clinical trials. Experimental and molecular therapeutics, .

Jiao, Y., Lawler, K., Patel, G.S., Purushotham, A., Jones, A.F., Grigoriadis, A., Tutt, A., Ng, T. & Teschendorff, A.E. (2011). DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. Bmc bioinformatics, Vol.12.

Basu, B., Ang, J.E., Crawley, D., Folkerd, E., Sarker, D., Blanco-Codesido, M., Moran, K., Wan, S., Dobbs, N., Raynaud, F., et al. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor-(ER) or androgen receptor (AR)-positive advanced breast carcinoma resistant to standard endocrine therapies. Journal of clinical oncology, Vol.29 (15).

Basu, B., Ang, J.E., Crawley, D., Folkerd, E., Sarker, D., Blanco-Codesido, M., Moran, K., Wan, S., Dobbs, N., Raynaud, F., et al. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. J clin oncol, Vol.29 (15_suppl), p. 2525.  show abstract

Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M.A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010). FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer res, Vol.70 (5), pp. 2085-2094.  show abstract

Yap, T.A., de Bono, J.S., Kaye, S.B., Tutt, A., Ashworth, A. & Schellens, J.H. (2010). Reply to J Veeck et al. J clin oncol, .

Molyneux, G., Geyer, F.C., Magnay, F.-., McCarthy, A., Kendrick, H., Natrajan, R., Mackay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell stem cell, Vol.7 (3), pp. 403-417.  show abstract

Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M.A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010). FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer research, Vol.70 (5), pp. 2085-2094.  show abstract

Stebbing, J., Ellis, P. & Tutt, A. (2010). PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future oncology, Vol.6 (4), pp. 485-486.

Pichert, G., Jacobs, C., Jacobs, I., Menon, U., Manchanda, R., Johnson, M., Hamed, H., Firth, C., Evison, M., Tutt, A., et al. (2010). Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Familial cancer, Vol.9 (3), pp. 313-319.

Cazet, A., Lefebvre, J., Adriaenssens, E., Julien, S., Bobowski, M., Grigoriadis, A., Tutt, A., Tulasne, D., Le Bourhis, X. & Delannoy, P., et al. (2010). G(D3) Synthase Expression Enhances Proliferation and Tumor Growth of MDA-MB-231 Breast Cancer Cells through c-Met Activation. Molecular cancer research, Vol.8 (11), pp. 1526-1535.

Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J clin oncol, Vol.28 (15), pp. 2512-2519.  show abstract

Uva, P., Lahm, A., Sbardellati, A., Grigoriadis, A., Tutt, A. & de Rinaldis, E. (2010). Comparative Membranome Expression Analysis in Primary Tumors and Derived Cell Lines. Plos one, Vol.5 (7).

Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, Vol.376 (9737), pp. 245-251.

Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, Vol.376 (9737), pp. 235-244.

Lau, A., McCormack, P., Mangena, R., Gaboriau, D., Knights, C., Unwin, L., Wu, P., Cranston, A., Boss, D., Mergui-Roelvink, M., et al. (2009). A pharmacodynamic (PD) evaluation of the PARP inhibitor olaparib (AZD2281) in a first-in-human Phase I trial of patients with advanced solid tumours. Cancer research, Vol.69.

Lau, A., McCormack, P., Mangena, R., Gaboriau, D., Knights, C., Unwin, L., Wu, P., Cranston, A., Boss, D., Mergui-Roelvink, M., et al. (2009). A pharmacodynamic (PD) evaluation of the PARP inhibitor olaparib (AZD2281) in a first-in-human Phase I trial of patients with advanced solid tumours. Cancer research, Vol.69.

Iverson, A.A., Gillett, C., Cane, P., Santini, C.D., Vess, T.M., Kam-Morgan, L., Wang, A., Eisenberg, M., Rowland, C.M., Hessling, J.J., et al. (2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. Journal of molecular diagnostics, Vol.11 (2), pp. 117-130.

Natrajan, R., Lambros, M.B., Rodríguez-Pinilla, S.M., Moreno-Bueno, G., Tan, D.S., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L.G., et al. (2009). Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clinical cancer research : an official journal of the american association for cancer research, Vol.15 (8), pp. 2711-2722.  show abstract

Loi, S., Haibe-Kains, B., Lallemand, F., Pusztai, L., Tutt, A., Gillett, C.E., Piccart, M., Phillips, W.A., McArthur, G. & Sotiriou, C., et al. (2009). PIK3CA, AKT1 MUTATION AND HER2 AMPLIFICATION GENE SIGNATURES (GS) SUGGEST PREDOMINANTLY NEGATIVE FEEDBACK INHIBITION OF PI3K/AKT PATHWAY IN HUMAN BREAST CANCER (BC). Annals of oncology, Vol.20, pp. 45-45.

Rhiem, K., Wappenschmidt, B., Bosse, K., Koeppler, H., Tutt, A.N. & Schmutzler, R.K. (2009). Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer. Clinical oncology, Vol.21 (6), pp. 448-450.

Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N engl j med, Vol.361 (2), pp. 123-134.  show abstract

Natrajan, R., Lambros, M.B., Rodriguez-Pinilla, S.M., Moreno-Bueno, G., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L.G., et al. (2009). Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clin cancer res, Vol.15 (8), pp. 2711-2722.  show abstract

Tutt, A., Robson, M., Garber, J.E., Domchek, S., Audeh, M.W., Weitzel, J.N., Friedlander, M. & Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J clin oncol, Vol.27 (18_suppl), p. CRA501.  show abstract

Tutt, A., Robson, M., Garber, J.E., Domchek, S., Audeh, M.W., Weitzel, J.N., Friedlander, M. & Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J clin oncol, Vol.27 (15_suppl), p. CRA501.  show abstract

Reis-Filho, J.S. & Tutt, A.N. (2008). Triple negative tumours: a critical review. Histopathology, Vol.52 (1), pp. 108-118.  show abstract

Turner, N.C., Lord, C.J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A.N. & Ashworth, A. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo j, Vol.27 (9), pp. 1368-1377.  show abstract

Tutt, A. & Ashworth, A. (2008). Can genetic testing guide treatment in breast cancer?. Eur j cancer, Vol.44 (18), pp. 2774-2780.  show abstract

Tutt, A., Wang, A., Rowland, C., Gillett, C., Lau, K., Chew, K., Dai, H., Kwok, S., Ryder, K., Shu, H., et al. (2008). Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. Bmc cancer, Vol.8.

Hiley, C., Tutt, A., Torres, M. & Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer. British medical journal, Vol.337.

Turner, N.C., Reis, J.S., Russell, A.M., Springall, R.J., Ryder, K., Steele, D., Savage, K., Gillett, C.E., Schmitt, F.C., Ashworth, A., et al. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, Vol.26 (14), pp. 2126-2132.  show abstract

Turner, N.C., Reis-Filho, J.S., Russell, A.M., Springall, R.J., Ryder, K., Steele, D., Savage, K., Gillett, C.E., Schmitt, F.C., Ashworth, A., et al. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, Vol.26 (14), pp. 2126-2132.

Rakha, E.A., Tan, D.S., Foulkes, W.D., Ellis, I.O., Tutt, A., Nielsen, T.O. & Reis-Filho, J.S. (2007). Are triple-negative tumours and basal-like breast cancer synonymous?. Breast cancer res, Vol.9 (6), p. 404.

Shanley, S., McReynolds, K., Ardern-Jones, A., Ahern, R., Fernando, I., Yarnold, J., Evans, G., Eccles, D., Hodgson, S., Ashley, S., et al. (2006). Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin cancer res, Vol.12 (23), pp. 7025-7032.  show abstract

Shanley, S., McReynolds, K., Ardern-Jones, A., Ahern, R., Fernando, I., Yarnold, J., Evans, G., Eccles, D., Hodgson, S., Ashley, S., et al. (2006). Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin cancer res, Vol.12 (23), pp. 7033-7038.  show abstract

Tutt, A. & Yarnold, J. (2006). Radiobiology of Breast Cancer. Clinical oncology, Vol.18 (3), pp. 166-178.

de Bono, J.S., Fong, P.C., Boss, D., Spicer, J., Roelvink, M., Tutt, A., Mortimer, P., O'Connor, M., Schellens, J.H. & Kaye, S.B., et al. (2006). Phase I pharmacolkinetic (PK) and pharmacodynamic (PD) evaluation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advanced tumours. Ejc suppl, Vol.4 (12), pp. 153-153.

McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer res, Vol.66 (16), pp. 8109-8115.  show abstract

Fong, P.C., Spicer, J., Reade, S., Reid, A., Vidal, L., Schellens, J.H., Tutt, A., Harris, P.A., Kaye, S. & De Bono, J.S., et al. (2006). Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J clin oncol, Vol.24 (18_suppl), p. 3022.  show abstract

Turner, N., Tutt, A. & Ashworth, A. (2005). Targeting the DNA repair defect of BRCA tumours. Curr opin pharmacol, Vol.5 (4), pp. 388-393.  show abstract

McCabe, N., Lord, C.J., Tutt, A.N., Martin, N.M., Smith, G.C. & Ashworth, A. (2005). BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-Ribose) polymerase. Cancer biol ther, Vol.4 (9), pp. 934-936.  show abstract

McCabe, N., Lord, C.J., Tutt, A.N., Martin, N., Smith, G.C. & Ashworth, A. (2005). BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency. Cancer biology & therapy, Vol.4 (9), pp. 934-936.

Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, Vol.434 (7035), pp. 917-921.  show abstract

Turner, N., Tutt, A. & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nat rev cancer, Vol.4 (10), pp. 814-819.  show abstract

Gudmundsdottir, K., Lord, C.J., Witt, E., Tutt, A.N. & Ashworth, A. (2004). DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. Embo rep, Vol.5 (10), pp. 989-993.  show abstract

Tutt, A., Connor, F., Bertwistle, D., Kerr, P., Peacock, J., Ross, G. & Ashworth, A. (2003). Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. Oncogene, Vol.22 (19), pp. 2926-2931.  show abstract

Tutt, A.N., van Oostrom, C.T., Ross, G.M., van Steeg, H. & Ashworth, A. (2002). Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. Embo rep, Vol.3 (3), pp. 255-260.  show abstract

Tutt, A. & Ashworth, A. (2002). The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends mol med, Vol.8 (12), pp. 571-576.  show abstract

Tutt, A., Bertwistle, D., Valentine, J., Gabriel, A., Swift, S., Ross, G., Griffin, C., Thacker, J. & Ashworth, A. (2001). Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo j, Vol.20 (17), pp. 4704-4716.  show abstract

Tutt, A.N., Bertwistle, D., Valentine, J., Gabriel, A., Swift, S., Ross, G.M., Griffin, C., Thacker, J. & Ashworth, A. (2001). Mutation in BRCA2 reduces use of error-free DNA repair by sister chromatid recombination and stimulates error-prone DNA repair by homology directed single-strand annealing. Breast cancer res tr, Vol.69 (3), pp. 255-255.

Tutt, A., Gabriel, A., Bertwistle, D., Connor, F., Paterson, H., Peacock, J., Ross, G. & Ashworth, A. (1999). Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr biol, Vol.9 (19), pp. 1107-1110.  show abstract

Tutt, A.N., A'hern, R. & Henk, J.M. (1998). Cervical node metastasis of unknown primary site: The Royal Marsden Hospital 15 year experience. Brit j cancer, Vol.78, pp. 6-6.

de Rinaldis, E., Gazinska, P., Mera, A., Modrusan, Z., Fedorowicz, G.M., Burford, B., Gillett, C., Marra, P., Grigoriadis, A., Dornan, D., et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. Bmc genomics, (14).

Tutt, A., Brasó-Maristany, F., Filosto, S., Catchpole, S., marlow, R., quist, J., Francesch-Domenech, E., plumb, D., zaikai, L., Gazinska, P., et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature medicine, .

Dowsett, M., Lawler, K., Papouli, E., Naceur-Lombardelli, C., Mera, A., Ougham, K., Tutt, A., Kimbung, S., Hedenfalk, I., Zhan, J., et al. Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast cancer research, .

morris, J., koo, C., gianomini, C., reyes-corral, M., olmos, Y., tavares, I., marson, C., linardopoulos, S. & tutt, A. Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Molecular cancer therapeutics, .

Naidoo, K., Wai, P., Maguire, S., Daley, F., Haider, S., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A., Tutt, A., et al. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer. Molecular cancer therapeutics, .

Grigoriadis, A., Gazinska, P., Pai, T., Irhsad, S., Wu, Y., Millis, R., Naidoo, K., Owen, J., Gillett, C., Tutt, A., et al. Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph nodepositive breast cancers. The journal of pathology: clinical research, .

Bajrami, I., Marlow, R., van de Ven, M., Brough, R., Pemberton, H., Frankum, J., Song, F., Raquif, R., Konde, A., Krastev, D., et al. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer. Cancer discovery, .

Nirmesh, P., Weekes, D., Drosopoulos, K., Gazinska, P., Noel, E., Rashid, M., Mirza, H., Quist, J., Brasó-Maristany, F., Sumi, M., et al. Integrated genomics and functional validation identifies malignant cell specific dependencies in Triple Negative Breast Cancer. Nature communications, .

Tutt, A., Tovey, H., Cheang, M., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and 2 pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial 3 4. Nature medicine, .


Conferences

Schmid, P., Wheatley, D., Baird, R., Chan, S., Abraham, J., Tutt, A., Kristeleit, H., Patel, G., Bathakur, U., Bishop, J., et al. (2016). Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603), Presented at Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX, Ongoing Clinical Trials, .

Robson, M., Tutt, A., Balmaña, J., Kaufman, B., Garber, J., Geyer, C., Ford, J., Sharma, P., Stuart, M., Mann, H., et al. (2015). Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germlineBRCA1/2mutation (gBRCAm), Presented at Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX, Ongoing Clinical Trials, .

Ilieva, K.M., Marlow, R., Cheung, A., Francesch, E., Karagiannis, P., Fittall, M., Crescioli, S., Tutt, A. & Karagiannis, S. (2015). Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Immunology, .

Lawler, K., Papouli, E., Tutt, A., Ng, T., Pinder, S., Parker, P., Holmberg, L., Gillett, C., Grigoriadis, A. & Purushotham, A., et al. (2015). Clinical patterns of metastatic spread from formalin-fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients, ANNALS OF ONCOLOGY, Vol.26.

Tutt, A. (2014). DESIGNING CLINICAL TRIALS IN A POST NEO-ADJUVANT SETTING, ANNALS OF ONCOLOGY, Vol.25.

Tryfonidis, K., Bogaerts, J., Martell, R.E., Sledge, G.W., Balmaña, J., Audeh, M.W., Deleersnijder, A., Favorito, F., Agarwal, S., Rizzetto, G., et al. (2014). A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS659.

Kyle, F., Wu, Y., Nussbaumer, O., Hessey, S., Tutt, A. & Hayday, A. (2013). Characterisation of Tumour-Infiltrating Lymphocytes in primary breast cancer, IMMUNOLOGY, Vol.140, p.19.

A'Hern, R., Gillett, C., Pinder, S., Kalaitzaki, E., Bliss, J., Tutt, A., Barrett-Lee, P., Ellis, P. & Johnston, S. (2013). Abstract P6-06-03: Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT), Presented at Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX, Poster Session Abstracts, .

Grigoriadis, A., Gazinska, P., Rasmussen, M., Isaksson, A., de Rinaldis, E., Mathew, S., Marra, P., Gillett, C., Pinder, S. & Tutt, A., et al. (2012). EXPRESSION OF HORMAD1, A CANCER/TESTIS ANTIGEN, IN TRIPLE-NEGATIVE BREAST CANCERS WITH HIGH GENOMIC INSTABILITY, ANNALS OF ONCOLOGY, Vol.23, p.37.

Sninsky, J.J., Christopherson, C., Lagier, R., Chang, M., Kwok, S., Tandon, V., Moore, D.H., Waldman, F., Degnim, A.C., Ingle, J.N., et al. (2012). Multiplex TaqMan assays for a 7-gene prognostic immune response score to differentiate risk among women with ER-negative breast cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Gazinska, P., Grigoriadis, A., Springall, R., Bosshard-Carter, L., Woodman, N., Rashid, M., deRinaldis, E., Marra, P., Brown, J., Pinder, S., et al. (2011). Evaluation of Nucleic Acid Quality From Long-Time Stored Fresh-Frozen Breast Cancer Tissues After Non-Automated Needle Micro-Dissection., JOURNAL OF PATHOLOGY, Vol.224, p.S27.

Marra, P., Twiddy, D., Maristany, F.B., Noel, E., Mathew, S., Gazinska, P., Grigoriadis, A., Rashid, M., de Rinaldis, E. & Tutt, A., et al. (2011). IDENTIFICATION AND VALIDATION OF PUTATIVE ONCOGENIC DRIVER GENES IN TRIPLE NEGATIVE BREAST CANCER (TNBC): THE ROLE OF IL15RA, ANNALS OF ONCOLOGY, Vol.22, p.51.

White, A.L., Chan, H.T., French, R.R., Roghanian, A., Mockridge, C.I., Tutt, A.L., Verbeek, J.S., Noelle, R.J., Al-Shamkhani, A., Cragg, M.S., et al. (2011). Essential cross-linking role for FcgRIIB in the in vivo activity of anti-CD40 monoclonal antibody, IMMUNOLOGY, Vol.135, p.189.

Tutt, A. (2010). EARLY PHASE PROOF OF CONCEPT STUDIES AND RATIONALE FOR PATIENT SELECTION, ANNALS OF ONCOLOGY, Vol.21, p.22.

Izatt, L., Jacobs, C., Jacobs, I., Menon, U., Manchanda, R., Johnson, M., Hamed, H., Firth, C., Evison, M., Tutt, A., et al. (2010). Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers, JOURNAL OF MEDICAL GENETICS, Vol.47, p.S116.

Tutt, A. (2010). LATER TALES: PHASE II AND BEYOND, ANNALS OF ONCOLOGY, Vol.21, p.26.

Natrajan, R., Rodriguez-Pinilla, S.M., Lambros, M.B., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Moreno-Bueno, G., Fulford, L.G., Mackay, A., et al. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. LABORATORY INVESTIGATION, Vol.89, p.59A.

Natrajan, R., Rodriguez-Pinilla, S.M., Lambros, M.B., Tan, D.S., Marchio, C., Vatcheva, R., Rayter, S., Moreno-Bueno, G., Fulford, L.G., Mackay, A., et al. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, Presented at 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA. MODERN PATHOLOGY, Vol.22, p.59A.

Tutt, A., Gillett, C., Pinder, S., A'Hern, R.P., Dowsett, M., Ellis, I.O., Bartlett, J., Bliss, J.M., Johnston, S., Ellis, P., et al. (2009). Microtubule Associated Protein Tau Expression as a Predictive and Prognostic Marker in a Trial Assessing Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT)., Presented at 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX. CANCER RESEARCH, Vol.69 (24), p.523S.

Tutt, A., Robson, M., Garber, J.E., Domchek, S., Audeh, M.W., Weitzel, J.N., Friedlander, M. & Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (18).

Audeh, M.W., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Carmichael, J. & Tutt, A. (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15).

Reis, J.S., Turner, N., Schmitt, F.C., Tutt, A. & Ashworth, A. (2006). BRCA1 gene promoter methylation in metaplastic breast carcinomas, Presented at 190th Meeting of the Pathological-Society-of-Great-Britain-and-Ireland, Manchester, ENGLAND. JOURNAL OF PATHOLOGY, Vol.210, p.59.

Tutt, A.N., van Oostrom, C., Ross, G.M., van Steeg, H. & Ashworth, A. (2001). Loss of BRCA2 increases in vivo somatic mutation induction by ionising radiation., BREAST CANCER RES TR, Vol.69 (3), p.255.

Tutt, A., Gabriel, A., Bertwistle, B., Connor, F., Paterson, H., Peacock, J., Ross, G. & Ashworth, A. (2000). Absence of BRCA2 causes genomic instability, BRIT J CANCER, Vol.83, p.25.

Ashworth, A., Bertwistle, D., Conner, F., Gabriel, A., Kerr, P., Marston, N., Partridge, N., Smith, A., Swift, S., Tutt, A., et al. (1999). Analysis of the breast cancer susceptibility gene BRCA2, BRIT J CANCER, Vol.80, p.4.

Ross, G., Tutt, A., Bertwhistle, D. & Ashworth, A. (1998). Role of BRCA2 in DNA repair: Implications for breast carcinogenesis and therapy., BRIT J CANCER, Vol.78, p.25.

In this section

Research overview Research projects Publications